World Investment Advisors LLC Significantly Boosts Stake in Eli Lilly and Company

World Investment Advisors LLC has dramatically increased its investment in Eli Lilly and Company (NYSE:LLY) by an astonishing 1,566.8% during the third quarter. This information comes from the firm’s recent 13F filing with the Securities and Exchange Commission (SEC). Following this substantial increase, the fund now owns 217,966 shares after acquiring an additional 204,889 shares in this period.

Eli Lilly and Company now represents about 1.1% of World Investment Advisors LLC's total holdings, making it the fund's 13th largest investment. The value of their stake in Eli Lilly amounted to approximately $193,105,000 as of the latest reporting date.

Recent Activity of Other Investors

In addition to World Investment Advisors LLC, several other notable investors have recently adjusted their positions in Eli Lilly. For instance, International Assets Investment Management LLC has drastically increased its ownership by 87,091.7% in the third quarter, now holding a significant 12,463,182 shares valued at $11,041,631,000 after purchasing an additional 12,448,888 shares.

Furthermore, UBS AM, a division of UBS Asset Management Americas LLC, has raised its stake by 2.6%, owning 6,115,504 shares valued at around $5,417,970,000 after acquiring 157,741 shares during the same period. Similarly, Fisher Asset Management LLC has increased its holdings by 3.5%, bringing its total to 5,058,101 shares worth approximately $4,481,175,000 after buying an extra 169,391 shares.

Other investors such as Dimensional Fund Advisors LP and Ameriprise Financial Inc. also boosted their stakes in Eli Lilly during previous quarters. Overall, institutional investors and hedge funds own approximately 82.53% of the company's stock.

Analyst Ratings Updates

Recent evaluations from various equity research analysts have also indicated a bullish sentiment towards Eli Lilly shares. Truist Financial recently increased their price target from $1,000.00 to $1,033.00 and maintains a "buy" rating. Citigroup raised their target from $1,060.00 to a notable $1,250.00, also tagging the stock as a "buy." Meanwhile, Sanford C. Bernstein began coverage with an "outperform" rating and a target price of $1,100.00. Redburn Atlantic and Wells Fargo have provided mixed evaluations, with the latter boosting its price objective from $875.00 to $1,000.00.

Overall, the consensus among analysts indicates a "Moderate Buy" rating, with an average target price of $1,007.94 based on data from MarketBeat.com.

Stock Performance Overview

Eli Lilly's stock opened at $826.66 recently, with a 52-week range between $561.65 and $972.53. Its 50-day simple moving average stands at $843.71, while the 200-day average is at $870.75. With a market cap of $784.76 billion, the company holds a P/E ratio of 89.37 and a price-to-earnings-growth ratio of 3.14.

Recent Earnings and Dividend Announcement

On October 30, Eli Lilly disclosed its earnings, revealing a loss of $1.18 per share, falling short of the expected $1.52. Meanwhile, the company reported revenues totaling $11.44 billion, below analyst forecasts of $12.09 billion.

The firm also announced a quarterly dividend of $1.30 per share payable on December 10 to investors on record as of November 15, culminating in an annual yield of 0.63%.

Insider Trading Activities

In insider news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly at an average price of $803.38, totaling $723,042. Following this sale, he holds 5,480 shares. This transaction marks a 14.11% reduction in his ownership.

Company Overview

Eli Lilly and Company engages in discovering, developing, and marketing human pharmaceuticals globally, with various products targeting conditions such as diabetes and obesity.

Eli Lilly, Investors, Stock, Growth, Earnings